These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26965928)

  • 1. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
    Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
    World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
    Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
    Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
    Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
    Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line.
    Zheng Q; Zhao LY; Kong Y; Nan KJ; Yao Y; Liao ZJ
    World J Surg Oncol; 2013 Jan; 11():5. PubMed ID: 23311997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
    Salehi S; Saljooghi ASh; Shiri A
    Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
    Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
    Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
    Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
    Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
    Li Y; Tian X; Sui CG; Jiang YH; Liu YP; Meng FD
    Biomed Pharmacother; 2016 Aug; 82():498-508. PubMed ID: 27470390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
    Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
    Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
    Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
    Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
    [No Abstract]   [Full Text] [Related]  

  • 16. Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells.
    Jeong JB; Hong SC; Jeong HJ; Koo JS
    Int Immunopharmacol; 2011 Oct; 11(10):1573-7. PubMed ID: 21621647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Iron Chelation in Osteosarcoma.
    Argenziano M; Di Paola A; Tortora C; Di Pinto D; Pota E; Di Martino M; Perrotta S; Rossi F; Punzo F
    Curr Cancer Drug Targets; 2021; 21(5):443-455. PubMed ID: 33380300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
    Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
    Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
    Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.